Janssen Pharmaceuticals, a division of Johnson & Johnson, is facing 40 percent more Risperdal serious side effect lawsuits today than it did just a year ago.
The lead attorneys in Philadelphia have added more than 500 new suits to the docket since the beginning of 2017. J&J lawyers are now even more aggressive in the wake of a $70 million verdict in March 2017; before then, the company had settled many of these actions for as little as $2,000 a case. One source says that J&J is refusing to settle and doing “whatever it takes” to win cases, such as bringing a new stable of expert witnesses to court. On top of the Risperdal lawsuits, the company is dealing with multiple verdicts regarding the link between talcum powder and ovarian cancer, in addition to an ongoing parade of defective hip implant cases. There are more claims on the horizon as well, as the first Xarelto trial is scheduled to begin in April 2017; these victims claim that the blood thinner causes uncrontrolled bleeding.